AZD4635 Relative Bioavailability Study

NCT03710434 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: AZD4635 50 mg nano-suspension (reference)
DRUG: AZD4635 solid oral formulation - fasted
DRUG: AZD4635 solid oral formulation - fed
DRUG: Lansoprazole and AZD4635 50 mg solid oral formulation
DRUG: AZD4635 solid oral formulation variant 1 - fasted
DRUG: AZD4635 solid oral formulation variant 2 - fasted
DRUG: [14C] AZD4635 IV microtracer - fasted

Sponsor

AstraZeneca

Collaborators

[object Object]